Legend Biotech (LEGN) is back in the spotlight after third quarter 2026 results showed a move to profitability, stronger CARVYKTI sales, and fresh FDA progress on its next CAR T candidate. Despite the...
Source LinkLegend Biotech (LEGN) is back in the spotlight after third quarter 2026 results showed a move to profitability, stronger CARVYKTI sales, and fresh FDA progress on its next CAR T candidate. Despite the...
Source Link
Comments